XENON PHARMACEUTICALS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.68 USD | -1.46% |
|
-1.27% | -18.33% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 352.6 | 554 | 1,643 | 2,466 | 3,503 | 2,886 | - | - |
| Enterprise Value (EV) 1 | 352.6 | 377 | 1,092 | 1,874 | 2,572 | 2,159 | 2,236 | 2,124 |
| P/E ratio | -8.51 x | -19 x | -17.6 x | -19.1 x | -16.9 x | -13.1 x | -12 x | -11.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 51.6 x | 17.2 x | 89.1 x | 261 x | - | 1,539 x | 307 x | 47.6 x |
| EV / Revenue | 51.6 x | 11.7 x | 59.2 x | 199 x | - | 1,152 x | 238 x | 35.1 x |
| EV / EBITDA | -8.32 x | - | - | -14.7 x | -12.2 x | -9.46 x | -9.47 x | -9.02 x |
| EV / FCF | -60 x | -7.43 x | -15.3 x | -18.5 x | -17 x | -9.9 x | -9.69 x | -7.94 x |
| FCF Yield | -1.67% | -13.5% | -6.55% | -5.41% | -5.87% | -10.1% | -10.3% | -12.6% |
| Price to Book | - | - | - | 3.42 x | 3.74 x | 3.98 x | 5.94 x | 4.53 x |
| Nbr of stocks (in thousands) | 26,896 | 36,023 | 52,605 | 62,544 | 76,045 | 75,469 | - | - |
| Reference price 2 | 13.11 | 15.38 | 31.24 | 39.43 | 46.06 | 38.24 | 38.24 | 38.24 |
| Announcement Date | 3/9/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.829 | 32.17 | 18.44 | 9.434 | - | 1.875 | 9.389 | 60.59 |
| EBITDA 1 | -42.39 | - | - | -127.5 | -210.5 | -228.2 | -236 | -235.5 |
| EBIT 1 | -42.82 | -31.3 | -78.99 | -129.1 | -214.1 | -251 | -294.6 | -322.2 |
| Operating Margin | -627.02% | -97.31% | -428.45% | -1,368.91% | - | -13,387% | -3,137.57% | -531.82% |
| Earnings before Tax (EBT) 1 | -41.62 | -29.09 | -78.89 | -125.3 | -182.7 | -223.4 | -284.6 | -320.4 |
| Net income 1 | -40.03 | -28.01 | -77.09 | -124.9 | -182.4 | -224.6 | -268.7 | -305.9 |
| Net margin | -586.13% | -87.09% | -418.11% | -1,324.32% | - | -11,976.08% | -2,861.81% | -504.88% |
| EPS 2 | -1.540 | -0.8100 | -1.770 | -2.060 | -2.730 | -2.910 | -3.197 | -3.391 |
| Free Cash Flow 1 | -5.872 | -50.76 | -71.55 | -101.3 | -150.9 | -218 | -230.8 | -267.5 |
| FCF margin | -85.99% | -157.81% | -388.09% | -1,074.03% | - | -11,626.67% | -2,457.77% | -441.53% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/9/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.737 | 8.766 | 0.536 | 0.132 | - | - | - | - | - | - | - | - | 1.667 | - | - |
| EBITDA 1 | - | -16.99 | -29.94 | -37.77 | -42.82 | -48.7 | -55.02 | -53.95 | -52.84 | -58.44 | -57.9 | -58.63 | -59.42 | - | - |
| EBIT 1 | -24.84 | -17.37 | -30.32 | -38.13 | -43.33 | -49.05 | -55.62 | -55.68 | -53.7 | -59.04 | -61.72 | -66.46 | -68.61 | -72.79 | -92 |
| Operating Margin | -664.65% | -198.14% | -5,655.78% | -28,884.85% | - | - | - | - | - | - | - | - | -4,116.87% | - | - |
| Earnings before Tax (EBT) 1 | -25.08 | -20.06 | -31.2 | -37.74 | -36.26 | -41.44 | -47.68 | -48.62 | -44.95 | -47.52 | -55.02 | -59.83 | -61.52 | -73.2 | -83.8 |
| Net income 1 | -25.08 | -19.37 | -31.16 | -37.15 | -37.4 | -41.73 | -47.46 | -48.46 | -44.74 | -47.93 | -55.4 | -60.28 | -62.28 | -73.2 | -83.8 |
| Net margin | -671.05% | -220.98% | -5,813.06% | -28,143.94% | - | - | - | - | - | - | - | - | -3,736.94% | - | - |
| EPS 2 | -0.4800 | -0.3500 | -0.5500 | -0.5700 | -0.5700 | -0.6300 | -0.7200 | -0.7300 | -0.6400 | -0.6200 | -0.7074 | -0.7622 | -0.9383 | -0.7875 | -0.8300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/1/22 | 5/10/22 | 8/9/22 | 11/8/22 | 3/1/23 | 5/9/23 | 8/9/23 | 11/8/23 | 2/29/24 | 5/9/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 177 | 552 | 592 | 931 | 727 | 650 | 762 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -5.87 | -50.8 | -71.6 | -101 | -151 | -218 | -231 | -268 |
| ROE (net income / shareholders' equity) | - | - | - | -19.7% | -22.1% | -27% | -40.4% | -56.2% |
| ROA (Net income/ Total Assets) | - | - | - | -18.8% | -21.2% | -25.6% | -40.5% | -46.2% |
| Assets 1 | - | - | - | 663.1 | 859.5 | 878.6 | 663.3 | 662.1 |
| Book Value Per Share 2 | - | - | - | 11.50 | 12.30 | 9.600 | 6.440 | 8.450 |
| Cash Flow per Share 2 | - | - | - | -1.630 | -2.170 | -2.800 | -2.380 | - |
| Capex 1 | 1.24 | 2.64 | 2.05 | 2.89 | 5.62 | 2.75 | 2.75 | 3 |
| Capex / Sales | 18.16% | 8.2% | 11.12% | 30.68% | - | 146.67% | 29.29% | 4.95% |
| Announcement Date | 3/9/20 | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
38.24
USD
Average target price
58.79
USD
Spread / Average Target
+53.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.33% | 2.89B | |
| +17.97% | 125B | |
| +13.93% | 108B | |
| -6.95% | 23.64B | |
| +2.39% | 22.39B | |
| -12.11% | 17.78B | |
| -41.64% | 16.43B | |
| -14.67% | 16.34B | |
| +0.36% | 13.56B | |
| +24.37% | 11.59B |
- Stock Market
- Equities
- XENE Stock
- Financials Xenon Pharmaceuticals Inc.
